Investors

Pre-clinical Testing

C3 has successfully completed animal testing for a range of neurodegenerative diseases.

  • Effective in multiple animal models of CNS disease states
  • Successfully demonstrated efficacy in mice, rats, pigs and non-human primates
  • No toxicity or side effects at daily doses materially higher than therapeutic dosage levels
  • No animals died from taking C3 at doses materially higher than therapeutic dosage levels
  • Safe and successful animal testing supports our confidence that C3 also will be safe in humans
  • Most recently, Fullerene Therapeutics principal investigators have finished a comprehensive study of C3 in a non-human primate model of PD, recently published in the August 2014 issue of Annals of Neurology.

Strong indications of non-toxicity

In mouse studies, the fullerene compound C3 has been radio-isotope tagged prior to administration, so that upon autopsy, its accumulation could be measured. In those tests, there was no accumulation of the compound in the test animals. In addition, autopsy studies show no damage to organs, and no accumulation of the compound in the body.

Copyright 2019 Fullerene Therapeutics, Inc.
No part of the contents of this web site may be 
reproduced without express written permission.